is Chief Operating Officer at Ridgeline.
Andrew joined Versant in 2018 from Roche where he was VP Business Development at Roche Molecular Solutions in Pleasanton, CA. There he led the BD and Alliance Management team which successfully executed and integrated >75 deals including 10 acquisitions. Prior to that he held a wide variety of roles in Roche’s Pharma BD team and was previously the Basel Site Head for Roche Partnering.
Andrew began his career in pharmaceutical manufacturing and then moved into pharma business at Ciba-Geigy and Novartis in the UK. He holds a BSc in Chemistry from the University of Nottingham and an MBA from the University of Brighton.